BCLI

$0.85-11.18%visit website

BRAINSTORM CELL THERAPEUTICS INC.

Market Cap

$9M

Live price × SEC shares (Aug 11, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.37

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	899	852	762	963	3,476
Operating income	(2,047)	(2,244)	(2,046)	(3,613)	(9,950)
Net income	(2,106)	(2,434)	(2,127)	(3,855)	(10,522)
EPS (basic) ($)	(0.19)		(0.19)	(0.35)	—
EPS (diluted) ($)	(0.19)		(0.19)	(0.35)	—
Weighted avg. shares (basic)	11,008		11,035	11,035
Weighted avg. shares (diluted)	11,008		11,035	11,035

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

10 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 14, 2026 accepted 4:16 PM ET	2.02Earnings release	Document SEC ↗
Jul 30, 2026 accepted 4:30 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
May 28, 2026 accepted 4:05 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
May 15, 2026 accepted 5:00 PM ET	2.02Earnings release	Document SEC ↗
Mar 31, 2026 accepted 4:16 PM ET	2.02Earnings release	Document SEC ↗
Feb 27, 2026 accepted 4:24 PM ET	1.01Material agreement3.02Unregistered equity sale5.02Officer / director change	Document SEC ↗
Feb 13, 2026 accepted 4:31 PM ET	1.01Material agreement3.02Unregistered equity sale	Document SEC ↗
Jan 9, 2026 accepted 4:30 PM ET	1.01Material agreement3.02Unregistered equity sale	Document SEC ↗
Nov 14, 2025 accepted 4:45 PM ET	1.01Material agreement2.02Earnings release3.02Unregistered equity sale	Document SEC ↗
Nov 6, 2025 accepted 5:00 PM ET	1.01Material agreement3.02Unregistered equity sale	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

—

of daily vol

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

No Form 4 transactions on record.

Recent News

Brainstorm Cell Therapeutics Inc. (BCLI) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada · 2026-10-30

BrainStorm Cell Therapeutics Inc. Estimates – OTC:BCLI

TradingView · 2026-10-24

Brainstorm Cell Therapeutics Inc (OTC: BCLI) Share Price, BCLI Stock News, BCLI Share Price & Updates

kalkine.ca · 2026-10-04

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

Yahoo Finance · 2026-08-24

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Yahoo Finance · 2026-08-14

Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) Share Price, BCLI Stock News, BCLI Share Price & Updates

kalkine.ca · 2026-08-01

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

Yahoo Finance · 2026-07-28

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

Yahoo Finance · 2026-06-02

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

Yahoo Finance · 2026-05-28

BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

Yahoo Finance · 2026-05-19

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Yahoo Finance · 2026-05-15

BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

Yahoo Finance · 2026-03-31

BCLI Stock Price and Chart — OTC:BCLI

TradingView · 2025-07-19

What is the current Price Target and Forecast for Brainstorm Cell Therapeutics (BCLI)

Zacks Investment Research · 2022-08-27

Brainstorm Cell Therapeutics Stock Price Forecast. Should You Buy BCLI?

StockInvest.us · 2020-12-01

Informational purposes only, not investment advice.

Corporate Events (8-K)

10 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 14, 2026 accepted 4:16 PM ET	2.02Earnings release	Document SEC ↗
Jul 30, 2026 accepted 4:30 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
May 28, 2026 accepted 4:05 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
May 15, 2026 accepted 5:00 PM ET	2.02Earnings release	Document SEC ↗
Mar 31, 2026 accepted 4:16 PM ET	2.02Earnings release	Document SEC ↗
Feb 27, 2026 accepted 4:24 PM ET	1.01Material agreement3.02Unregistered equity sale5.02Officer / director change	Document SEC ↗
Feb 13, 2026 accepted 4:31 PM ET	1.01Material agreement3.02Unregistered equity sale	Document SEC ↗
Jan 9, 2026 accepted 4:30 PM ET	1.01Material agreement3.02Unregistered equity sale	Document SEC ↗
Nov 14, 2025 accepted 4:45 PM ET	1.01Material agreement2.02Earnings release3.02Unregistered equity sale	Document SEC ↗
Nov 6, 2025 accepted 5:00 PM ET	1.01Material agreement3.02Unregistered equity sale	Document SEC ↗

BCLI

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Factor Profile

Corporate Events (8-K)